Cargando…
Serum Chemerin as a Novel Prognostic Indicator in Chronic Heart Failure
BACKGROUND: It has been documented that circulating chemerin is associated with inflammation, metabolic syndrome, and coronary artery disease. The present study was aimed to evaluate the prognostic value of serum chemerin in patients with chronic heart failure. METHODS AND RESULTS: We included 834 p...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761658/ https://www.ncbi.nlm.nih.gov/pubmed/31333053 http://dx.doi.org/10.1161/JAHA.119.012091 |
_version_ | 1783454068505575424 |
---|---|
author | Zhou, Xiang Tao, Yifei Chen, Yuqi Xu, Weiting Qian, Zhiyuan Lu, Xiang |
author_facet | Zhou, Xiang Tao, Yifei Chen, Yuqi Xu, Weiting Qian, Zhiyuan Lu, Xiang |
author_sort | Zhou, Xiang |
collection | PubMed |
description | BACKGROUND: It has been documented that circulating chemerin is associated with inflammation, metabolic syndrome, and coronary artery disease. The present study was aimed to evaluate the prognostic value of serum chemerin in patients with chronic heart failure. METHODS AND RESULTS: We included 834 patients with chronic heart failure in a prospective cohort study and investigated the association between serum chemerin and clinical outcomes using multivariate Cox regression analysis. Patients with higher chemerin levels tended to be older and women and were more likely to experience hypertension, diabetes mellitus, and hyperlipemia. Cox regression analysis showed that chemerin was a significant predictor of major adverse cardiac events (hazard ratio, 1.83; 95% CI, 1.31–2.96) after adjustment for conventional risk factors. Net reclassification and integrated discrimination improvements for major adverse cardiac events were markedly improved by addition of chemerin to the reference model. In addition, chemerin was an independent predictor of all‐cause mortality (hazard ratio, 1.67; 95% CI, 1.21–2.73) after multivariable adjustment. Furthermore, the Kaplan–Meier survival analysis revealed that chemerin was a prognostic indicator of major adverse cardiac events in patients with chronic heart failure and NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) levels above and below the median. CONCLUSIONS: Our study suggests that chemerin is a novel serum marker for predicting major adverse cardiac events in patients with chronic heart failure. |
format | Online Article Text |
id | pubmed-6761658 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67616582019-09-30 Serum Chemerin as a Novel Prognostic Indicator in Chronic Heart Failure Zhou, Xiang Tao, Yifei Chen, Yuqi Xu, Weiting Qian, Zhiyuan Lu, Xiang J Am Heart Assoc Original Research BACKGROUND: It has been documented that circulating chemerin is associated with inflammation, metabolic syndrome, and coronary artery disease. The present study was aimed to evaluate the prognostic value of serum chemerin in patients with chronic heart failure. METHODS AND RESULTS: We included 834 patients with chronic heart failure in a prospective cohort study and investigated the association between serum chemerin and clinical outcomes using multivariate Cox regression analysis. Patients with higher chemerin levels tended to be older and women and were more likely to experience hypertension, diabetes mellitus, and hyperlipemia. Cox regression analysis showed that chemerin was a significant predictor of major adverse cardiac events (hazard ratio, 1.83; 95% CI, 1.31–2.96) after adjustment for conventional risk factors. Net reclassification and integrated discrimination improvements for major adverse cardiac events were markedly improved by addition of chemerin to the reference model. In addition, chemerin was an independent predictor of all‐cause mortality (hazard ratio, 1.67; 95% CI, 1.21–2.73) after multivariable adjustment. Furthermore, the Kaplan–Meier survival analysis revealed that chemerin was a prognostic indicator of major adverse cardiac events in patients with chronic heart failure and NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) levels above and below the median. CONCLUSIONS: Our study suggests that chemerin is a novel serum marker for predicting major adverse cardiac events in patients with chronic heart failure. John Wiley and Sons Inc. 2019-07-23 /pmc/articles/PMC6761658/ /pubmed/31333053 http://dx.doi.org/10.1161/JAHA.119.012091 Text en © 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Research Zhou, Xiang Tao, Yifei Chen, Yuqi Xu, Weiting Qian, Zhiyuan Lu, Xiang Serum Chemerin as a Novel Prognostic Indicator in Chronic Heart Failure |
title | Serum Chemerin as a Novel Prognostic Indicator in Chronic Heart Failure |
title_full | Serum Chemerin as a Novel Prognostic Indicator in Chronic Heart Failure |
title_fullStr | Serum Chemerin as a Novel Prognostic Indicator in Chronic Heart Failure |
title_full_unstemmed | Serum Chemerin as a Novel Prognostic Indicator in Chronic Heart Failure |
title_short | Serum Chemerin as a Novel Prognostic Indicator in Chronic Heart Failure |
title_sort | serum chemerin as a novel prognostic indicator in chronic heart failure |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761658/ https://www.ncbi.nlm.nih.gov/pubmed/31333053 http://dx.doi.org/10.1161/JAHA.119.012091 |
work_keys_str_mv | AT zhouxiang serumchemerinasanovelprognosticindicatorinchronicheartfailure AT taoyifei serumchemerinasanovelprognosticindicatorinchronicheartfailure AT chenyuqi serumchemerinasanovelprognosticindicatorinchronicheartfailure AT xuweiting serumchemerinasanovelprognosticindicatorinchronicheartfailure AT qianzhiyuan serumchemerinasanovelprognosticindicatorinchronicheartfailure AT luxiang serumchemerinasanovelprognosticindicatorinchronicheartfailure |